EGFR is an upstream regulator of mTOR and ERK-1/2 signaling cascade and its overexpression and aberrant mutational status have been reported in several human cancers including renal cancer (Cossu-Rocca et al., 2016; Sooro et al., 2018). This evidence concerns the gene MAPK3 and cancer.